Skip to content

Study on the intervention effect and mechanism of Lycium ruthenicum Murr. and Lycium barbarum on Parkinson's disease based on microbiomics and metabonomics

Study on the intervention effect and mechanism of Lycium ruthenicum Murr. and Lycium barbarum on Parkinson's disease based on microbiomics and metabonomics

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100047147
Enrollment
Unknown
Registered
2021-06-08
Start date
2021-06-17
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Interventions

control group:Nil
experimental group A:Lycium ruthenicum Murr. was consumed 12g per person per day
experimental group B:Lycium barbarum was consumed 12g per person per day

Sponsors

Ningxia Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary Parkinson's disease; 2. Hoehn & Yahr stage I-III; 3. Aged from 40 to 80 years; 4. BMI > 18.5; 5. On stable antiparkinsonian medication for at least 4 weeks prior to study enrollment; 6. Volunteered to participate in this study, patients and their family members signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Diagnosed dementia, major depression, psychosis; 2. Severe diseases of the digestive system, acute or chronic primary diseases of the gastrointestinal tract affecting gastrointestinal function, history of esophageal adhesions, strictures, varicose veins, bile duct and pancreatic diseases, history of gastrointestinal surgery, prior abdominal or anal surgery; 3. Have gastrointestinal and respiratory infections, food poisoning or nosebleeds in need of treatment in the past 2 months; 4. Drugs and substance abuse; 5. Cancer and endocrine diseases such as diabetes and hypothyroidism; 6. Stroke, myocardial infarction, heart failure, known background of severe renal insufficiency, arrhythmia, liver disease, uncontrolled hypertension, and hypokalemia; 7. Had taken health supplements containing excessive intakes of phenolic plant extracts within 3 months prior to intervention; 8. Antibiotics received within 3 months prior to intervention, probiotics, probiotics, and vitamin supplements, and other medical treatments may affect changes in intestinal flora; 9. Have the habit of drinking carbonated drinks, probiotics and prebiotics food; 10. Pregnant and lactating women; 11. Volunteers participating in other clinical trials.

Design outcomes

Primary

MeasureTime frame
gut microbiota;Blood Metabolomics;Urine metabolomics;

Countries

China

Contacts

Public ContactGao Qinghan

Ningxia Medical University

gaoqinghan85@126.com+86 18161506389

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026